RxDoctor Payments Data

Todd Clapp, MD

Internal Medicine · Oklahoma City, OKNPI 1013958321

Payments from drug & device makers

$744in general payments, 2019–2025

Across 46 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$234
  • AbbVie$117
  • GSK$83
  • Sanofi-aventis U.S. LLC$44
  • Dexcom, Inc.$36
  • Lilly USA, LLC$30
  • plus $201 from 10 others

What the payments were for

  • Food & beverage$744100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$744 in reported general payments places this provider in the 65th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$75,611
Medicare patients
188
Services billed
799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide60$82,884
JardianceEmpagliflozin58$79,803
EliquisApixaban64$62,699
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$47,587
Tresiba Flextouch U-200Insulin Degludec28$39,453
MounjaroTirzepatide20$30,299
JanuviaSitagliptin Phosphate54$29,246
OzempicSemaglutide19$26,403
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$12,592
OxycontinOxycodone Hcl12$11,785
LinzessLinaclotide16$11,330
Combivent RespimatIpratropium/Albuterol Sulfate18$9,107
SymbicortBudesonide/Formoterol Fumarate24$8,111
Spiriva HandihalerTiotropium Bromide15$7,906
XareltoRivaroxaban13$6,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$30$113,18380 claims
Boehringer IngelheimJardiance, Combivent Respimat$28$88,91076 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$83$64,77676 claims
PfizerEliquis$234$62,69964 claims
Novo NordiskOzempic$28$26,40319 claims
AbbVieLinzess, Savella$117$17,26829 claims
AstraZenecaSymbicort, Bevespi Aerosphere$28$13,45436 claims
Johnson & JohnsonXarelto$24$6,93913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →